Wu Jiang, Song Yu
Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Department of Respiration, The Central Hospital of Wuhan, Wuhan, Hubei 430014, P.R. China.
Oncol Lett. 2018 Mar;15(3):3447-3452. doi: 10.3892/ol.2018.7799. Epub 2018 Jan 15.
The aim of this study was to examine the changes of serum matrix metalloproteinase-7 (MMP-7) and phosphatase and tension homolog (PTEN) in patients with acute myeloid leukemia (AML) at different time points following treatment. The levels of serum MMP-7 and PTEN were measured from 80 AML patients with a diagnosis of peripheral blood, immune cell phenotype, and bone marrow puncture cytology examination. Among these, there were 20 cases of complete remission, 20 cases of primary untreated patients, 21 cases of incomplete remission, and 19 cases of relapse after remission. In addition, 20 healthy adults with normal physical examination results were enrolled as the control group. Patients were divided into different groups according to the treatment period. Serum MMP-7 and PTEN levels in patients and the healthy control group were measured using an ELISA. Compared with the control group, the levels of MMP-7 of 20 primary untreated patients were significantly increased (P<0.05), while there was no significant difference for the levels of PTEN in the incomplete remission group. A comparison between the control and complete remission groups revealed that the levels of MMP-7 and PTEN in the serum samples of 21 cases of patients with incomplete remission were significantly increased (P<0.05). In addition, the content of MMP-7 in 19 patients in relapse after remission group was significantly higher (P<0.05) than that of the complete remission and healthy control groups, while the levels of serum PTEN did not show significant changes. In conclusion, the level of serum MMP-7 and PTEN in AML patients was closely related to the clinical stage and the degree of disease. The combination of MMP-7 and PTEN may provide theoretical support for the accurate diagnosis, understanding of efficacy, prognosis and improvement of survival rate of AML.
本研究旨在探讨急性髓系白血病（AML）患者治疗后不同时间点血清基质金属蛋白酶-7（MMP-7）和磷酸酶及张力蛋白同源物（PTEN）的变化。选取80例经外周血诊断、免疫细胞表型及骨髓穿刺细胞学检查确诊的AML患者，检测其血清MMP-7和PTEN水平。其中，完全缓解20例，初治未治疗患者20例，部分缓解21例，缓解后复发19例。此外，选取20例体检结果正常的健康成年人作为对照组。根据治疗时期将患者分为不同组。采用酶联免疫吸附测定法（ELISA）检测患者及健康对照组血清MMP-7和PTEN水平。与对照组相比，20例初治未治疗患者的MMP-7水平显著升高（P<0.05），而部分缓解组的PTEN水平无显著差异。对照组与完全缓解组比较，21例部分缓解患者血清样本中的MMP-7和PTEN水平显著升高（P<0.05）。此外，缓解后复发组19例患者的MMP-7含量显著高于完全缓解组和健康对照组（P<0.05），而血清PTEN水平无显著变化。综上所述，AML患者血清MMP-7和PTEN水平与临床分期及疾病程度密切相关。MMP-7和PTEN的联合检测可能为AML的准确诊断、疗效评估、预后判断及生存率提高提供理论支持。
